Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis.

Autor: Alotaibi FT; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Peng B; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Klausen C; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Lee AF; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Abdelkareem AO; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Orr NL; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Noga H; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Bedaiwy MA; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada., Yong PJ; Department of Obstetrics & Gynaecology, BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, Canada.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2019 Jul 17; Vol. 14 (7), pp. e0219064. Date of Electronic Publication: 2019 Jul 17 (Print Publication: 2019).
DOI: 10.1371/journal.pone.0219064
Abstrakt: Purpose: Deep infiltrating endometriosis (DIE) is defined as an endometriotic lesion penetrating to a depth of >5 mm and is associated with pelvic pain, but the underlying mechanisms are unclear. Our objective is to investigate whether plasminogen activator inhibitor-1 expression (PAI-1) in endometriotic tissues is increased in women with DIE.
Methods: In this blinded in vitro study, immunohistochemistry and Histoscore were used to examine the expression of PAI-1 in glandular epithelium (GECs) and stroma (SCs) in a total of 62 women: deep infiltrating uterosacral/rectovaginal endometriosis (DIE; n = 13), ovarian endometrioma (OMA; n = 14), superficial peritoneal uterosacral/cul-de-sac endometriosis (SUP; n = 23), uterine (eutopic) endometrium from women with endometriosis (UE; n = 6), and non-endometriosis eutopic endometrium (UC; n = 6). The following patient characteristics were also collected: age, American Fertility Society stage, hormonal suppression, phase of menstrual cycle, dysmenorrhea score and deep dyspareunia score.
Results: PAI-1 expression in GECs and SCs of the DIE group was significantly higher than that of SUP group (p = 0.01, p = 0.01, respectively) and UE group (p = 0.03, p = 0.04, respectively). Interestingly, increased PAI-1 expression in GECs and SCs was also significantly correlated with increased dysmenorrhea (r = 0.38, p = 0.01; r = 0.34, p = 0.02, respectively).
Conclusions: We found higher expression of PAI-1 in DIE, and an association between PAI-1 and worse dysmenorrhea.
Competing Interests: Dr. Bedaiwy received lecture fees and served on advisory boards for Abbvie and Allergan, and received funding for research unrelated to the present study from Allergan (CAPTURE fibroid registry). This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development, or marketed products to declare.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje